Regeneron and Celltrion Settle Eylea Biosimilar Patent Fight

Regeneron Pharmaceuticals Inc. and Celltrion Inc. settled their patent lawsuit over Celltrion’s biosimilar version of Eylea, further shrinking Regeneron’s once-sprawling litigation campaign over the blockbuster eye-disease drug.

The deal would resolve all claims between the companies in litigation consolidated in the US District Court for the Northern District of West Virginia. A stipulation and proposed order filed Monday would dismiss the Celltrion leg of the case, vacate a 2024 preliminary injunction, and release a related bond.

Celltrion can launch its biosimilar in the US on Dec. 31, 2026, Regeneron said Monday in a statement, adding that the other terms ...